Gene Therapy Communication: Use of a Needs Assessment to Drive Decision-AIDS for Gene Therapy for Rare Diseases (GENETX)

• ClinicalTrials.gov Identifier: NCT05810181
• Recruitment Status: Recruiting
• First Posted: April 12, 2023
• Last Update Posted: November 15, 2023
• Sponsor: St. Jude Children's Research Hospital
• Information provided by (Responsible Party): St. Jude Children's Research Hospital

Study Description

Brief Summary:

This prospective mixed-method interview study aims to qualitatively describe the beliefs, attitudes, and informational needs around gene therapy for rare pediatric diseases among patients and parents of children with a rare disease targeted for treatment using gene therapy techniques. Using learned insights, the team will develop an online platform providing educational content and patient decision aids for patients and their families.

Condition or disease	Intervention/treatment
Sickle Cell Disease	Other: Interview

Detailed Description:

The study team seeks to understand the unique needs of patients and parents of children who are considering novel experimental gene therapy treatments. The study team will engage patient, caregiver, and healthcare worker stakeholders to understand their attitudes, beliefs, and concerns surrounding these treatments. Based on these insights, the team, with the support of the above stakeholders and an external vendor, will develop web platform offering educational content and decision aids to enhance their experience and overall satisfaction with the process of making treatment decisions. This is especially important as novel therapies for SCD will increasingly include gene editing in pediatric trials over the next two years. These efforts will address significant gaps in the educational material available to those considering gene therapy and (to the team's knowledge) will create a resource that will be the first of its kind.

Study Design

• Study Type: Observational
• Estimated Enrollment: 70 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Gene Therapy Communication: Use of a Needs Assessment to Drive Decision-AIDS for Gene Therapy for Rare Diseases (GENETX)
• Actual Study Start Date: June 1, 2023
• Estimated Primary Completion Date: December 2025
• Estimated Study Completion Date: December 2026

Groups and Cohorts

Group/Cohort	Intervention/treatment
Young Adult; 15-25 parents/families of children (or young adults aged 18-35 years) with rare genetic diseases, who have recently received gene therapy	Other: Interview; The following three groups of stakeholders will be interviewed to assess the beliefs, attitudes, and informational needs around gene therapy for rare pediatric diseases: (1) patients and families of children with rare genetic diseases who have received gene therapy (to assess their perspectives and understand their informational needs around participating in a clinical trial using gene therapy), (2) patients and families of children with rare genetic diseases who were offered but have decided against receiving gene therapy or ultimately did not qualify for a trial (to elicit feedback and to evaluate whether their informational needs and communication expectations about participating in a clinical trial using gene therapy were met), and (3) healthcare workers who provide care to patients receiving gene therapy (to assess their perspective regarding patient/family needs for gene therapy education and communication).
Parent/caregiver; 10-20 patients/families of children with rare genetic diseases who were offered but have decided against receiving gene therapy or who were ultimately not eligible for a clinical trial.	Other: Interview; The following three groups of stakeholders will be interviewed to assess the beliefs, attitudes, and informational needs around gene therapy for rare pediatric diseases: (1) patients and families of children with rare genetic diseases who have received gene therapy (to assess their perspectives and understand their informational needs around participating in a clinical trial using gene therapy), (2) patients and families of children with rare genetic diseases who were offered but have decided against receiving gene therapy or ultimately did not qualify for a trial (to elicit feedback and to evaluate whether their informational needs and communication expectations about participating in a clinical trial using gene therapy were met), and (3) healthcare workers who provide care to patients receiving gene therapy (to assess their perspective regarding patient/family needs for gene therapy education and communication).
Healthcare Worker; 10-20 health care workers' who provide care to patients receiving gene therapy.	Other: Interview; The following three groups of stakeholders will be interviewed to assess the beliefs, attitudes, and informational needs around gene therapy for rare pediatric diseases: (1) patients and families of children with rare genetic diseases who have received gene therapy (to assess their perspectives and understand their informational needs around participating in a clinical trial using gene therapy), (2) patients and families of children with rare genetic diseases who were offered but have decided against receiving gene therapy or ultimately did not qualify for a trial (to elicit feedback and to evaluate whether their informational needs and communication expectations about participating in a clinical trial using gene therapy were met), and (3) healthcare workers who provide care to patients receiving gene therapy (to assess their perspective regarding patient/family needs for gene therapy education and communication).

Outcome Measures

Primary Outcome Measures :

1. Use of semi-structured interviews to assess the beliefs, attitudes, and informational needs around gene therapy among patients and families with rare genetic diseases. [ Time Frame: 2 years ]
   Trained experts will interview study participants to elucidate their beliefs, attitudes, and informational needs around gene therapy for rare pediatric diseases among the disease stakeholders. These interviews will be analyzed via the well-described rigorous methodology of semantic content analysis to identify themes through a systematic and standardized process.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 35 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes
• Sampling Method: Non-Probability Sample

Study Population

About 45-50 young adults (age 18-35) or parents of children verified to have a rare disease targeted for treatment using gene therapy techniques and 10-20 healthcare workers who provide care to patients receiving gene therapy.

Criteria

Inclusion Criteria:

1. For Group 1 participants only (Undergone Gene Therapy):

   • Parent/caregiver whose child has undergone gene therapy. OR Young adult aged between 18 years to 35 years who has undergone gene therapy.
   • Willingness to participate in one-on-one video interview with a study team member using a personal mobile device or computer with working internet connection.
   • Must be willing to provide verbal informed consent.
   • Release of information form signed by participant providing our study team with permission to contact healthcare provider to verify their diagnosis and receipt of gene therapy (if received).
   • Successful verification of diagnosis of rare genetic disease targeted for treatment using gene therapy.
   • A positive confirmation on receipt of gene therapy and type received from their healthcare provider (only for those received gene therapy).

2. For Group 2 participants only (Offered, but did not Undergo Gene Therapy):

   • Parent/caregiver of children (or young adults aged between 18 years to 35 years) with a rare genetic disease who had been offered but were not eligible for a trial or decided against receiving gene therapy.
   • Willingness to participate in one-on-one video interview with a study team member using a personal mobile device or computer with working internet connection.
   • Must be willing to provide verbal informed consent.
   • Signed release of information form providing GeneTx study team with permission to contact participant's healthcare provider to verify the diagnosis.
   • Successful verification of diagnosis of rare genetic disease targeted for treatment using gene therapy.

3. For Group 3 participants only (Provider Interviews):

   • Healthcare worker who has provided care to ≥ 2 patients receiving gene therapy.
   • Willingness to participate in one-on-one video (or in-person) interview with a study team member using a personal mobile device or computer with working internet connection.
   • Informed consent from a study participant.

Exclusion Criteria:

• Participants who are unable to converse fluently in English will be excluded.
• Inability or unwillingness of research participant to give verbal informed consent.
• Participants who lack access to a computer or mobile device that supports video communications will be excluded.
• Condition or chronic illness, which in the opinion of the PI/Co-I, makes participation unsafe or untenable (i.e., cognitive impairment, concurrent acute morbidity).

Contacts and Locations

Contacts

Contact: Liza-Marie Johnson, MD, MPH, MSB; 8662785833; referralinfo@stjude.org

Locations

United States, Tennessee

St. Jude Children's Research Hospital; Recruiting

Memphis, Tennessee, United States, 38105

Contact 866-278-5833 referralinfo@stjude.org

Sponsors and Collaborators

St. Jude Children's Research Hospital

Investigators

• Principal Investigator: Liza-Marie Johnson, MD, MPH, MSB; St. Jude Children's Research Hospital

More Information

• Responsible Party: St. Jude Children's Research Hospital
• ClinicalTrials.gov Identifier: NCT05810181
• Other Study ID Numbers: GENETX
• First Posted: April 12, 2023
• Last Update Posted: November 15, 2023
• Last Verified: November 2023

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Anemia, Sickle Cell; Rare Diseases; Anemia, Hemolytic, Congenital; Anemia, Hemolytic; Anemia; Hematologic Diseases; Hemoglobinopathies; Genetic Diseases, Inborn; Disease Attributes; Pathologic Processes